Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis

The US Food and Drug Administration recently granted an approved indication for the first fixed-dose combination antihypertensive (amlodipine) and nonsteroidal anti-inflammatory drug (celecoxib) for treatment of comorbid hypertension and osteoarthritis. This review summarizes available data on this combination product, to be marketed as Consensi (Kitov Pharmaceuticals, Ltd, Tel Aviv, Israel), and discusses its potential place in therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *